Summit Therapeutics has reported its financial results and operational progress for the fourth quarter and year ended December 31, 2025. The company's experimental drugs, including ivonescimab for lung cancer and a colorectal cancer treatment, have shown promising results in trials, with the latter seeing a 70.8% response rate. However, the outcomes of these trials and the company's financial health are still being evaluated, with Summit potentially seeking additional funding to develop its lead candidate.